Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Change in Receivables (2021 - 2025)

Senti Biosciences has reported Change in Receivables over the past 5 years, most recently at -$362000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at -$362000.0 for Q4 2025, down 525.88% from a year ago — trailing twelve months through Dec 2025 was -$374000.0 (down 895.74% YoY), and the annual figure for FY2025 was -$374000.0, down 895.74%.
  • Change in Receivables for Q4 2025 was -$362000.0 at Senti Biosciences, up from -$1.9 million in the prior quarter.
  • Over the last five years, Change in Receivables for SNTI hit a ceiling of $1.9 million in Q4 2023 and a floor of -$1.9 million in Q3 2025.
  • Median Change in Receivables over the past 5 years was $39000.0 (2024), compared with a mean of $75882.4.
  • Peak annual rise in Change in Receivables hit 3774.36% in 2025, while the deepest fall reached 4946.15% in 2025.
  • Senti Biosciences' Change in Receivables stood at $50000.0 in 2021, then surged by 162.0% to $131000.0 in 2022, then soared by 1384.73% to $1.9 million in 2023, then tumbled by 95.63% to $85000.0 in 2024, then tumbled by 525.88% to -$362000.0 in 2025.
  • The last three reported values for Change in Receivables were -$362000.0 (Q4 2025), -$1.9 million (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.